India to Vietnam: Amphotericin Export Trade Route

To import Amphotericin formulations into Vietnam, the following approvals and registrations are necessary:

1. Product Registration: All pharmaceutical products must be registered with the Drug Administration of Vietnam (DAV) and granted Market Authorization (MA) before distribution. The registration dossier should include comprehensive information about the drug's quality, safety, and efficacy. (hmlf.vn)

2. Dossier Format: The registration dossier should be prepared in the Common Technical Document (CTD) format, encompassing modules on administrative information, quality, non-clinical, and clinical data.

3. Timelines for Approval: The approval process duration can vary based on the completeness of the submitted dossier and the DAV's review workload.

4. Product Registration Fees: Specific fees for product registration are determined by the DAV and may vary depending on the product type and registration category.

5. GMP Inspection Requirements: Foreign manufacturing facilities, including those in India, must comply with Good Manufacturing Practices (GMP) standards recognized by Vietnam. The DAV may require GMP certificates or conduct inspections to verify compliance.

Indian exporters of Amphotericin formulations must meet the following GMP certifications to supply products to Vietnam:

1. GMP Certification: Manufacturing facilities must hold GMP certificates issued by competent authorities, ensuring adherence to quality standards.

2. Approved Indian Facilities: Specific information regarding currently approved Indian facilities for exporting Amphotericin formulations to Vietnam is not publicly disclosed.

3. Recent Inspections or Regulatory Actions: There is no publicly available information on recent inspections or regulatory actions by the National DRA (ASEAN MRA) against Indian pharmaceutical companies as of March 2026.

In the past 18 months, several regulatory changes have impacted pharmaceutical imports into Vietnam:

1. Decree No. 88/2023/NĐ-CP: Issued on December 11, 2023, this decree provides updated guidelines on the import procedures for pharmaceutical materials, including active ingredients and excipients. (medgate.vn)

2. GMP Compliance Emphasis: Vietnam has intensified its focus on GMP compliance, requiring foreign manufacturers to adhere to internationally recognized GMP standards.

These developments underscore Vietnam's commitment to ensuring the quality and safety of imported pharmaceutical products.

Amphotericin formulations are critical in treating severe fungal infections, particularly in immunocompromised patients. Vietnam's healthcare sector has been expanding, with total health expenditure reaching approximately $17 billion in 2024, accounting for about 6.5% of the country's GDP. This growth is driven by an aging population and increased prevalence of non-communicable diseases, leading to higher demand for antifungal medications like Amphotericin.

Vietnam relies significantly on imports for specialized pharmaceuticals, including Amphotericin formulations, due to limited domestic production capabilities in this segment. In 2024, the country imported Amphotericin formulations valued at approximately $4.7 million from India alone, indicating a substantial dependence on foreign suppliers to meet domestic demand.

Pharmaceutical products classified under HS code 30049029, including Amphotericin formulations, are subject to a 0% MFN import duty rate in Vietnam. Additionally, these products are exempt from Value Added Tax (VAT), reducing the overall cost burden on importers and consumers.

Vietnam and India are both members of the ASEAN-India Free Trade Area (AIFTA), which aims to promote trade by reducing or eliminating tariffs on various goods, including pharmaceuticals. Under this agreement, pharmaceutical imports from India benefit from preferential tariff rates, further facilitating the importation of essential medicines into Vietnam.

India is a major supplier of Amphotericin formulations to Vietnam, accounting for approximately 5.3% of India's total Amphotericin formulation exports, valued at $88.0 million. The primary Indian exporters include Bharat Serums and Vaccines Limited and Lyka Labs Limited. On the Vietnamese side, key importers are Maxxcare Company Limited, OPV Pharmaceutical Joint Stock Company, and Delta Import-Export Medical Co., Ltd.

Other countries supplying Amphotericin formulations to Vietnam include China and various European Union (EU) member states. While specific import values from these countries are not detailed here, India's significant share indicates its competitive pricing and established trade relationships. Indian pharmaceutical products are generally priced more competitively compared to those from the EU, attributed to lower production costs and economies of scale. Chinese manufacturers also offer competitive pricing; however, India's established presence and compliance with international quality standards provide it with a strategic advantage in the Vietnamese market.

India is a global leader in the production of generic pharmaceuticals, supplying approximately 20% of the world's generic medicines by volume as of 2024. The country's pharmaceutical industry is valued at an estimated US$50 billion in FY 2023-24 and is projected to reach $130 billion by 2030.

The nation boasts over 650 U.S. Food and Drug Administration (FDA)-approved manufacturing facilities, surpassing the United States in the number of FDA-registered generic manufacturing sites. Additionally, India has 2,050 World Health Organization Good Manufacturing Practices (WHO-GMP)-certified plants as of 2024.

India's cost-effective production capabilities are bolstered by a skilled workforce and favorable regulatory environments, enabling the manufacture of high-quality finished dosage forms, including tablets, capsules, syrups, and injections. This efficiency extends to the production of formulations containing Amphotericin, ensuring competitive pricing without compromising quality.

When comparing Amphotericin formulations from India, China, and the European Union (EU), several factors come into play:

• Cost: India's pharmaceutical industry is renowned for its cost-effective production, supplying around 20% of global generic medicines by volume. This efficiency often results in lower prices for finished dosage forms compared to those from China and the EU.

• Quality Perception: Indian pharmaceutical companies have established a strong reputation for quality, with over 650 FDA-approved manufacturing facilities. This extensive regulatory approval underscores the industry's commitment to maintaining high standards.

• Regulatory Acceptance in Vietnam: Vietnam's pharmaceutical market recognizes and accepts imports from India, facilitated by India's adherence to international quality standards and its significant role in global pharmaceutical supply chains.

• Supply Reliability: India's pharmaceutical exports have been growing at a rate of 9%, nearly twice the global average, indicating a robust and reliable supply chain.

India's pharmaceutical manufacturing capacity is substantial, with the industry valued at an estimated US$50 billion in FY 2023-24 and projected to reach $130 billion by 2030. The country produces over 60,000 generic drugs across 60 therapeutic categories, demonstrating its extensive manufacturing capabilities.

The presence of over 650 FDA-approved facilities and 2,050 WHO-GMP-certified plants as of 2024 ensures compliance with stringent international quality standards. This regulatory adherence minimizes the risk of supply disruptions.

While specific data on recent supply disruptions for Amphotericin formulations are limited, India's overall pharmaceutical export growth and manufacturing scale suggest a reliable supply chain. However, buyers should remain vigilant and maintain open communication with suppliers to promptly address any potential issues.

For Vietnamese buyers sourcing Amphotericin formulations from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply of Amphotericin formulations.

• Minimum Order Quantities (MOQs): Understand the MOQs set by Indian suppliers, which can vary based on the manufacturer and specific product. Negotiating favorable MOQs can optimize inventory management and cost efficiency.

• Payment Terms: Familiarize yourself with common payment terms in India-Vietnam pharmaceutical trade, such as Letters of Credit (LC) or advance payments, to establish mutually beneficial agreements.

• Supplier Qualification Process: Implement a thorough qualification process, including audits of manufacturing facilities, verification of regulatory certifications (e.g., FDA, WHO-GMP), and assessment of quality control systems to ensure product quality and compliance.

• Regulatory Compliance: Stay informed about Vietnam's import regulations and ensure that selected Indian suppliers can provide the necessary documentation and support to meet these requirements.

By adopting these strategies, Vietnamese buyers can effectively source high-quality Amphotericin formulations from India, leveraging the country's manufacturing advantages and ensuring a reliable supply chain.

By adhering to these guidelines, Vietnamese pharmaceutical companies can establish robust supplier relationships with Indian manufacturers, ensuring the quality and safety of Amphotericin formulations imported into Vietnam.